Answers are grounded in this paper and cite their sources.
Theoretical model explores mechanism-based inhibition of mutant isocitrate dehydrogenase 1 in leukemia, suggesting new opportunities for targeted drug design.
First Iteration of a working theory on use of MBIs on IDH1 mutant enzymes to investigate potential therapies against a certain type of Leukemia
No takes yet. Share an insight, caveat, or question.
Harry Jansen (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: